Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000734111 | SCV000862227 | uncertain significance | not provided | 2018-07-03 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001306869 | SCV001496254 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2D | 2021-08-26 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid with histidine at codon 283 of the SGCA protein (p.Asp283His). The aspartic acid residue is weakly conserved and there is a moderate physicochemical difference between aspartic acid and histidine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals affected with SGCA-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Genome- |
RCV001306869 | SCV003931704 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2D | 2023-02-08 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001306869 | SCV002087580 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2D | 2019-11-11 | no assertion criteria provided | clinical testing |